Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
E4Sgpj6hke2zAfKw
Listen
